SoftOx Solutions AS — Share Issue/Capital Change 2024

Mar 27, 2024

SOFTX; Private placement, debt conversion and subsequent offering resolved by the extraordinary general meeting

SOFTX; Private placement, debt conversion and subsequent offering resolved by the extraordinary general meeting

The extraordinary general meeting in Soft-Ox Solutions AS was held Wednesday 27 March 2024.

All agenda items were approved in line with the proposals in the extraordinary general meeting notice with the amendments set out in the notices from the Company earlier today.

See separate press release with key information relating to the subsequent offering, with the following key information:

Last day including right: 27 March 2024

Ex-date: 2 April 2024

Record date: 3 April 2024

Date of approval: 27 April 2024

Maximum number of new shares: 125,000,000

Subscription price: NOK 0,2

The Company will provide update on the subsequent offering in a separate notice.

The minutes from the Extraordinary General Meeting in Norwegian and English are attached.

For any questions or interview requests, please contact:

Geir Almås, Chair of SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Geir Almås: (+47) 977 59 071

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and is headquartered in Oslo. The SoftOx Solutions Group includes: the holding company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly effective antimicrobial solution for use in biofilm, viral and antimicrobial resistant infections. The patent-protected technology is based on extensive research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com